Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-29
DOI
10.1038/s41467-018-06890-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma
- (2017) Taku Fujimura et al. Oncotarget
- Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
- (2017) Jing Liao et al. Cancer Immunology Research
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
- (2017) Jan Willem Kleinovink et al. OncoImmunology
- miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients
- (2016) András Lánczky et al. BREAST CANCER RESEARCH AND TREATMENT
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
- (2016) Haidong Tang et al. CANCER CELL
- CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
- (2016) Zhenhua Ren et al. CLINICAL CANCER RESEARCH
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN Combined with Chemotherapy
- (2016) D. H. Sterman et al. CLINICAL CANCER RESEARCH
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
- (2014) Xuanming Yang et al. CANCER CELL
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature
- (2014) Robbert M. Spaapen et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- High efficiency cell-specific targeting of cytokine activity
- (2014) Geneviève Garcin et al. Nature Communications
- Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
- (2014) T. Bald et al. Cancer Discovery
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
- (2012) Xuanming Yang et al. MOLECULAR THERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8+ T cells
- (2010) Sandra Hervas-Stubbs et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy
- (2010) Juan Dubrot et al. INTERNATIONAL JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now